drugset / Trial / NCT06469853
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-015 oral treatment during 28 days in Huntington's Disease patients on top of standard of care.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2024-12-04
- Completion
- 2024-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBF-015 | Unknown | 16 mg | Oral |
| Subject | MBF-015 | Unknown | 32 mg | Oral |